March 2, 2024

John­son & John­son’s Janssen on Fri­day earned an FDA ap­proval for its can­cer drug Ry­bre­vant (ami­van­tam­ab-vmjw) for the first-line treat­ment of lo­cal­ly ad­vanced or metasta­t­ic

The FDA is aim­ing to make it eas­i­er for clin­i­cal tri­al par­tic­i­pants to un­der­stand in­formed con­sent, of­fer­ing tri­al spon­sors rec­om­men­da­tions for clar­i­fy­ing key in­for­ma­tion, as

En­do agreed to pay up to $464.9 mil­lion to re­solve claims around the mar­ket­ing of its for­mer opi­oid pain med­ica­tion Opana ER. The com­pa­ny this

Ar­rakis Ther­a­peu­tics has pri­or­i­tized its pipeline and re­duced its head­count by about 20% this week, the biotech’s CEO said in a state­ment to End­points News.

Pfiz­er hopes that its cur­rent pipeline could de­liv­er at least eight can­cer block­buster drugs by 2030 as part of its strat­e­gy to dou­ble down on

HHS’ newest bio­med­ical re­search arm has yet to fi­nal­ize its char­ter for its ad­vi­so­ry com­mit­tee or ex­plain how mem­bers will put their heads to­geth­er to

At its meet­ing in At­lanta this week, the CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices rec­om­mend­ed Covid-19 boost­ers for old­er adults and a Val­ne­va chikun­gun­ya virus

In­smed wants to rec­og­nize pa­tients who feel un­seen or ig­nored, pub­lish­ing a new sur­vey, host­ing a pan­el dis­cus­sion with celebri­ty par­tic­i­pants and de­but­ing a new